Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Oct 13, 2008
Thursday and Friday of last week saw continued heavy trading in Boston Scientific's (NYSE: BSX) stock. As anticipated in the Company's October 9th...
-
Oct 12, 2008
Two-year pooled ARRIVE data showed the TAXUS Stent reduced clinical restenosis in patients with diabetes as effectively as in patients without diabetes
-
Oct 12, 2008
New coronary stent features thin struts designed for more uniform drug delivery
-
Oct 10, 2008
TAXUS Liberte drug eluting stent, launched in Europe and other international markets in 2005, to launch in U.S. next month
-
Oct 10, 2008
Company will also present results from the ARRIVE diabetic subset analysis, the ATLAS Workhorse and Direct Stenting trials and ATLAS data on small vessels and long lesions
-
Oct 9, 2008
The recent turmoil in the financial markets and bankruptcy of Lehman Brothers triggered automatic share selling
-
Oct 8, 2008
Company to discuss these and other issues on its third quarter earnings call on October 23 at 8:00 a.m.
-
Oct 8, 2008
PERSEUS clinical program to evaluate TAXUS® Element™ Platinum Chromium Stent
-
Oct 1, 2008
Judgment against Company entered in a patent case filed in 1997; Company to appeal
-
Sep 25, 2008
Company also announces FDA approval of TAXUS® Express2™ Stent System for treatment of in-stent restenosis